---
annotation-target: 20406207221115005.pdf
---


>%%
>```annotation-json
>{"created":"2022-09-13T02:36:59.594Z","updated":"2022-09-13T02:36:59.594Z","document":{"title":"Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation","link":[{"href":"urn:x-pdf:49d791f73b2acb3b842f3e5dde6e95e0"},{"href":"vault:/hematology-theroy/papers/20220831/20406207221115005.pdf"}],"documentFingerprint":"49d791f73b2acb3b842f3e5dde6e95e0"},"uri":"vault:/hematology-theroy/papers/20220831/20406207221115005.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/20406207221115005.pdf","selector":[{"type":"TextPositionSelector","start":1421,"end":1942},{"type":"TextQuoteSelector","exact":"Although extramedullary manifestations (EMs) are frequent in patients with acute myeloid leukemia (AML), they are often not detected during clinical workup and neither imaging- nor molecularly based diagnostic strategies are established to reveal their existence. Still, the detection of EM is essential for therapeutic decision-making, as EM present with aggressive and resistant disease and since mutational profiling might render patients within a different risk category, requiring personalized therapeutic strategies","prefix":"and Friedrich StölzelAbstract:  ","suffix":". Here, we report the case of an"}]}]}
>```
>%%
>*%%PREFIX%%and Friedrich StölzelAbstract:%%HIGHLIGHT%% ==Although extramedullary manifestations (EMs) are frequent in patients with acute myeloid leukemia (AML), they are often not detected during clinical workup and neither imaging- nor molecularly based diagnostic strategies are established to reveal their existence. Still, the detection of EM is essential for therapeutic decision-making, as EM present with aggressive and resistant disease and since mutational profiling might render patients within a different risk category, requiring personalized therapeutic strategies== %%POSTFIX%%. Here, we report the case of an*
>%%LINK%%[[#^2yedxipbx3c|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^2yedxipbx3c


>%%
>```annotation-json
>{"created":"2022-09-13T02:39:08.269Z","updated":"2022-09-13T02:39:08.269Z","document":{"title":"Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation","link":[{"href":"urn:x-pdf:49d791f73b2acb3b842f3e5dde6e95e0"},{"href":"vault:/hematology-theroy/papers/20220831/20406207221115005.pdf"}],"documentFingerprint":"49d791f73b2acb3b842f3e5dde6e95e0"},"uri":"vault:/hematology-theroy/papers/20220831/20406207221115005.pdf","target":[{"source":"vault:/hematology-theroy/papers/20220831/20406207221115005.pdf","selector":[{"type":"TextPositionSelector","start":23321,"end":23678},{"type":"TextQuoteSelector","exact":"The PETAML trial determined a median number of two EM sites per patient (range 1–12), a finding that was also con-firmed in our patient with both skin and medias-tinal  involvement  at  diagnosis.  A  lesson  learnt  from  this  case  vignette  is  the  added  information  that may be derived from repetitive biopsies with histological and molecular workup","prefix":"ures or happens by coincidence. ","suffix":". Also, repeated 18FDG-PET imagi"}]}]}
>```
>%%
>*%%PREFIX%%ures or happens by coincidence.%%HIGHLIGHT%% ==The PETAML trial determined a median number of two EM sites per patient (range 1–12), a finding that was also con-firmed in our patient with both skin and medias-tinal  involvement  at  diagnosis.  A  lesson  learnt  from  this  case  vignette  is  the  added  information  that may be derived from repetitive biopsies with histological and molecular workup== %%POSTFIX%%. Also, repeated 18FDG-PET imagi*
>%%LINK%%[[#^5gwsod93gtf|show annotation]]
>%%COMMENT%%
>
>%%TAGS%%
>
^5gwsod93gtf
